Eli Lilly funded many clinical trials on different patient demographics to test Dulaglutide for its effects in controlling blood sugar levels and weight loss
When combined with a balanced diet and regular physical activity, it can significantly enhance long-term results
The manufacturers' patient information leaflets (PILs) and Summaries of Product Characteristics (SmPCs) provide clear guidance on approved injection sites to optimise treatment outcomes and patient safety
It is not for veterinary use or animal consumption
Certain medications may trigger nightmares
Additional benefits observed: Substantial reduction in knee osteoarthritis pain (75.8% reduction in pain scores) Improved cardiovascular risk markers (non-HDL cholesterol, triglycerides, blood pressure) Up to 86% of participants with fatty liver disease achieved normal liver fat levels Early research suggests retatrutide may lead to substantial weight loss in clinical trial settings, but long-term safety, tolerability, and real-world outcomes still need more data